Much of the focus of the preeclampsia research field span across these four categories: “prediction”, “prevention”, “treatments”, and “outcomes” from preeclampsia (short- and long-term morbidity and mortality). The highest risk/reward research, but arguably the most difficult, is in the prevention and treatment categories. Right now, low-dose aspirin is the most common medication consistently recommended to lower risk for preeclampsia. There is a lack of any other medications/therapeutics on the market approved to prevent or cure preeclampsia once it develops. (It is important to note that magnesium sulfate is highly effective and approved for preventing and treating eclamptic seizures. It does not, however, halt the progression of the high blood pressure which characterizes preeclamspia.)
Research is being done to make a medicine that can cure preeclampsia a reality. In this article, researchers asked: what are the candidate medicines being studied currently to prevent or treatment preeclampsia? After an extensive review of the literature and clinical trial databases, researchers of this article identified 87 candidate medicines in clinical development. Within that list, researchers classified 7 as “high potential” and 8 as “medium potential”. Some of the candidate medicines for preventing preeclampsia listed include: esomeprazole, L-arginine, vitamin D, metformin, probiotic lactobacilli, selenium. Some of the candidate medicines listed for treatment of preeclampsia included: sulfasalazine, metformin, pravastatin, and omega-3 fatty acid.
Take home message: Research that puts together all of the current research in one place is helpful to set the direction for new studies and research funding. Gathering information on all the potential preeclampsia treatments or preventions in one article, to report and evaluate what has been done so far, helps move the research & development field for preeclampsia medicines forward.
Link: https://rdcu.be/cYYyS
Citation: McDougall ARA, Hastie R, Goldstein M, Tuttle A, Tong S, Ammerdorffer A, Gülmezoglu AM, Vogel JP. Systematic evaluation of the pre-eclampsia drugs, dietary supplements and biologicals pipeline using target product profiles. BMC Med. 2022 Nov 4;20(1):393. doi: 10.1186/s12916-022-02582-z. PMID: 36329468; PMCID: PMC9635102.
Each quarter, our team of researchers reviews the most current studies related to hypertensive disorders of pregnancy and selects those studies they feel will be of greatest interest to our community to summarize.
Special thanks to our volunteer research team, who under the leadership of Dr. Elizabeth Sutton, make Research Roundup possible: Alisse Hauspurg, MD Felicia LeMoine, and MD Jenny Sones, PhD, DVM.
Preeclampsia is a major cause of maternal and fetal morbidity and mortality. Prompt and accurate diagnosis is necessary to prevent adverse outcomes. A study was completed to determine the accura...
Predicting preeclampsia has proven to be a challenge. Researchers have documented many differences in early pregnancy between those who eventually develop preeclampsia and those who do not. These incl...
The U.S. Preventive Services Task Force (USPSTF) and American College of Obstetricians and Gynecologists (ACOG) guidelines changed in 2021 to help prevent preeclampsia. Low-dose aspirin has been shown...
Hypertensive disorders of pregnancy (HDP), including preeclampsia, affect 1 in 6 pregnancies. HDP is a general term for a range of mild to severe outcomes. Until now there has not been a reliabl...
Although there is no definitive treatment for preeclampsia, early screening and detection can allow patients to ensure proper management throughout the remainder of the pregnancy. Currently, preeclam...